CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction

Abroad (travel likely)Recruiting

Conditions

B-cell Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia, in Relapse · Refractory Acute Lymphoid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing GoBroad Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Tengyu Wang) · tengyu.wang@gohealtharo.com · 86+18333186020

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

B-NHL · B-Non Hodgkin Lymphoma · Acute Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Leukemia · Acute Myeloid Leukemia in Remission · Myelodysplasia

Abroad (travel likely)Recruiting

Milwaukee, United States

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

B-ALL · Leukemia

Abroad (travel likely)RecruitingPHASE1

Johannesburg, South Africa · Pretoria, South Africa

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoid Leukemia · Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Aurora, United States